Merrimack Pharmaceuticals (NASDAQ:MACK) Director Michael E. Porter acquired 15,000 shares of Merrimack Pharmaceuticals stock in a transaction dated Monday, May 5th. The shares were purchased at an average cost of $6.41 per share, for a total transaction of $96,150.00. Following the purchase, the director now directly owns 485,865 shares in the company, valued at approximately $3,114,395. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares after opening at $6.31 moved to $7.07 on last trade day and at the end of the day closed at $1111. Company price to sales ratio in past twelve months was calculated as 15.35 and price to cash ratio as 4.57. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) showed a positive weekly performance of 54.73%.
Specifically, CEO Fusen Ernie Chen bought 20,000 shares of Mattson Technology Inc.(NASDAQ:MTSN) stock in a transaction dated Thursday, May 1st. The shares were purchased at an average cost of $1.93 per share, with a total value of $38,600.00. Mattson Technology, Inc.(NASDAQ:MTSN) shares advanced 6.99% in last trading session and ended the day on $1.99. MTSN return on equity ratio is recorded as -33.80% and its return on assets is -13.20%. Mattson Technology, Inc.(NASDAQ:MTSN) yearly performance is 18.45%.
VistaPrint Limited (NASDAQ:VPRT) Director Eric C. Olsen acquired 4,000 shares of VistaPrint Limited stock on the open market in a transaction that occurred on Friday, May 2nd. The stock was purchased at an average cost of $39.57 per share, for a total transaction of $158,280.00. Following the completion of the purchase, the director now directly owns 9,097 shares in the company, valued at approximately $359,968. VistaPrint Limited (NASDAQ:VPRT) shares moved up 3.62% in last trading session and was closed at $40.64, while trading in range of $ 38.63 – 41.24. VistaPrint Limited (NASDAQ:VPRT) year to date (YTD) performance is -28.51
MedAssets news, Director R Halsey Wise purchased 8,950 shares of the MedAssets, Inc. (NASDAQ:MDAS)s stock on the open market in a transaction dated Friday, May 2nd. The stock was purchased at an average cost of $22.31 per share, with a total value of $199,674.50. Following the completion of the acquisition, the director now directly owns 8,950 shares of the company’s stock, valued at approximately $199,675. MedAssets, Inc. (NASDAQ:MDAS) weekly performance is -2.18%. On last trading day company shares ended up $22.39. MedAssets, Inc. (NASDAQ:MDAS) distance from 50-day simple moving average (SMA50) is -7.14%. Analysts mean target price for the company is $25.45.